CN101799476B - 筛选针对tsh受体的自身抗体的试剂盒 - Google Patents
筛选针对tsh受体的自身抗体的试剂盒 Download PDFInfo
- Publication number
- CN101799476B CN101799476B CN2010101273436A CN201010127343A CN101799476B CN 101799476 B CN101799476 B CN 101799476B CN 2010101273436 A CN2010101273436 A CN 2010101273436A CN 201010127343 A CN201010127343 A CN 201010127343A CN 101799476 B CN101799476 B CN 101799476B
- Authority
- CN
- China
- Prior art keywords
- tsh receptor
- autoantibody
- amino acids
- tsh
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000003911 Thyrotropin Receptors Human genes 0.000 title claims abstract description 923
- 108090000253 Thyrotropin Receptors Proteins 0.000 title claims abstract description 923
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 10
- 238000007873 sieving Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 328
- 229920001184 polypeptide Polymers 0.000 claims abstract description 206
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 206
- 238000012544 monitoring process Methods 0.000 claims abstract description 22
- 150000001413 amino acids Chemical class 0.000 claims description 448
- 108010061174 Thyrotropin Proteins 0.000 claims description 65
- 210000002966 serum Anatomy 0.000 claims description 64
- 102000011923 Thyrotropin Human genes 0.000 claims description 59
- 238000012360 testing method Methods 0.000 claims description 34
- 210000001685 thyroid gland Anatomy 0.000 claims description 32
- 238000012216 screening Methods 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 230000004936 stimulating effect Effects 0.000 claims description 13
- 238000002372 labelling Methods 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- 230000000155 isotopic effect Effects 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 abstract description 15
- 239000010839 body fluid Substances 0.000 abstract description 15
- 230000009471 action Effects 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 445
- 239000012634 fragment Substances 0.000 description 243
- 241001597008 Nomeidae Species 0.000 description 230
- 210000004698 lymphocyte Anatomy 0.000 description 193
- 125000003275 alpha amino acid group Chemical group 0.000 description 150
- 230000003993 interaction Effects 0.000 description 100
- 238000000034 method Methods 0.000 description 89
- 239000002773 nucleotide Substances 0.000 description 74
- 125000003729 nucleotide group Chemical group 0.000 description 74
- 208000023275 Autoimmune disease Diseases 0.000 description 60
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 59
- 102100029337 Thyrotropin receptor Human genes 0.000 description 59
- 230000028993 immune response Effects 0.000 description 42
- 230000027455 binding Effects 0.000 description 36
- 108091033319 polynucleotide Proteins 0.000 description 34
- 239000002157 polynucleotide Substances 0.000 description 34
- 102000040430 polynucleotide Human genes 0.000 description 34
- 108020003175 receptors Proteins 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 238000003745 diagnosis Methods 0.000 description 32
- 230000005764 inhibitory process Effects 0.000 description 32
- 102000005962 receptors Human genes 0.000 description 32
- 241000894007 species Species 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 206010020850 Hyperthyroidism Diseases 0.000 description 19
- 238000011534 incubation Methods 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000000470 constituent Substances 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 241000282326 Felis catus Species 0.000 description 12
- 241001494479 Pecora Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000012875 competitive assay Methods 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
- 238000013016 damping Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000003599 detergent Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 150000003833 nucleoside derivatives Chemical class 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 101710153593 Albumin A Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000005495 thyroid hormone Substances 0.000 description 6
- 229940036555 thyroid hormone Drugs 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 229950001470 thyrotrophin Drugs 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- 230000036963 noncompetitive effect Effects 0.000 description 4
- 230000000849 parathyroid Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 239000012749 thinning agent Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 102000014169 Steroid 21-Hydroxylase Human genes 0.000 description 2
- 108010011732 Steroid 21-Hydroxylase Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000011953 bioanalysis Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 102000047612 human CCN2 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000001948 isotopic labelling Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 101100080611 Caenorhabditis elegans nsf-1 gene Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000014267 Thyroid peroxidases Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000860832 Yoda Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- -1 aliphatic amino acid Chemical class 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000599 auto-anti-genic effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920012128 methyl methacrylate acrylonitrile butadiene styrene Polymers 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0120649A GB0120649D0 (en) | 2001-08-23 | 2001-08-23 | Epitope regions of a thyrotrophin (TSH) receptor and uses thereof |
| GB0120649.9 | 2001-08-23 | ||
| GB0215212.2 | 2002-07-01 | ||
| GB0215212A GB0215212D0 (en) | 2002-07-01 | 2002-07-01 | Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN028164229A Division CN1622958B (zh) | 2001-08-23 | 2002-08-21 | 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101799476A CN101799476A (zh) | 2010-08-11 |
| CN101799476B true CN101799476B (zh) | 2013-01-02 |
Family
ID=26246470
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101273436A Expired - Lifetime CN101799476B (zh) | 2001-08-23 | 2002-08-21 | 筛选针对tsh受体的自身抗体的试剂盒 |
| CN201310075812.8A Expired - Lifetime CN103224562B (zh) | 2001-08-23 | 2002-08-21 | 促甲状腺素受体的表位区域和针对该区域的抗体 |
| CN028164229A Expired - Lifetime CN1622958B (zh) | 2001-08-23 | 2002-08-21 | 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310075812.8A Expired - Lifetime CN103224562B (zh) | 2001-08-23 | 2002-08-21 | 促甲状腺素受体的表位区域和针对该区域的抗体 |
| CN028164229A Expired - Lifetime CN1622958B (zh) | 2001-08-23 | 2002-08-21 | 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8298769B2 (OSRAM) |
| EP (3) | EP1456234B1 (OSRAM) |
| JP (2) | JP2005509412A (OSRAM) |
| CN (3) | CN101799476B (OSRAM) |
| ES (3) | ES2732276T3 (OSRAM) |
| WO (1) | WO2003018632A2 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101799476B (zh) | 2001-08-23 | 2013-01-02 | Rsr有限公司 | 筛选针对tsh受体的自身抗体的试剂盒 |
| JP5314234B2 (ja) * | 2002-11-29 | 2013-10-16 | アールエスアール リミテッド | チロトロピン受容体の結合対象及びその使用 |
| EP1612224B1 (en) | 2004-06-29 | 2012-03-07 | B.R.A.H.M.S GmbH | Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine |
| GB0418181D0 (en) | 2004-08-13 | 2004-09-15 | Rsr Ltd | Thyrotrophin receptor preparations,thyrotrophin receptor epitopes,antibody and hormone interactions therewith,and uses thereof |
| WO2007057778A2 (en) * | 2005-11-21 | 2007-05-24 | Dr. Fenning Biomed Gmbh | Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against tsh receptor |
| JP5165672B2 (ja) * | 2006-03-29 | 2013-03-21 | キングス カレッジ ロンドン | Ｔｓｈｒに対するアゴニスト抗体 |
| ES2550158T3 (es) * | 2007-08-06 | 2015-11-04 | Chugai Seiyaku Kabushiki Kaisha | Método para medir la actividad inhibidora sobre la unión ligando-receptor |
| EP2617735A3 (en) * | 2008-12-24 | 2013-10-16 | Rsr Limited | Human anti tshr antibodies |
| KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| KR102585625B1 (ko) * | 2014-12-24 | 2023-10-05 | 아피토프 인터내셔날 엔브이 | 조성물 |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| EP3380620B1 (en) | 2015-11-23 | 2024-07-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
| CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| AU2018355427A1 (en) | 2017-10-25 | 2020-04-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US12441815B2 (en) | 2018-11-02 | 2025-10-14 | The Regents Of The University Of California | Compositions and methods for diagnosis of cardiovascular disease |
| US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| KR20220116522A (ko) | 2019-12-20 | 2022-08-23 | 노파르티스 아게 | 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도 |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| KR20250057832A (ko) * | 2022-08-31 | 2025-04-29 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 갑상선 자극 호르몬 수용체에 결합하는 항체 및 이의 용도 |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814461A (en) * | 1993-08-20 | 1998-09-29 | B.R.A.H.M.S. Diagnostica Gmbh | Method for the determination of anti-TSH receptor autoantibodies |
| EP0943098B1 (de) * | 1996-12-09 | 2005-03-09 | B.R.A.H.M.S Aktiengesellschaft | Rezeptorbindungsassay zum nachweis von tsh-rezeptor-autoantikörpern |
| EP1021721B1 (en) * | 1998-06-06 | 2006-08-09 | Rsr Limited | Assays for tsh receptor autoantibodies |
| EP1078986B1 (en) * | 1999-08-24 | 2007-02-28 | Tosoh Corporation | Secretory thyroid stimulating hormone receptor (TSHR), and method for assaying anti-TSHR antibody using the same |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4244940A (en) | 1978-09-05 | 1981-01-13 | Bio-Rad Laboratories, Inc. | Single-incubation two-site immunoassay |
| US4514498A (en) | 1982-05-26 | 1985-04-30 | The Board Of Regents, The University Of Texas System | Hybrid cell lines producing monoclonal antibodies directed against Treponema |
| US4472508A (en) | 1982-12-30 | 1984-09-18 | The Beth Israel Hospital Association | Test for detecting and measuring the graves' disease-specific immunoglobulins |
| WO1984003106A1 (en) | 1983-02-04 | 1984-08-16 | Wadley Inst Of Molecular Medic | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| US4609622A (en) | 1983-05-31 | 1986-09-02 | Interthyr Research Foundation Inc. | Clinical determination and/or quantification of thyrotropin and a variety of thyroid stimulatory or inhibitory factors performed in vitro with an improved thyroid cell line, FRTL-5 |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4661446A (en) | 1985-02-19 | 1987-04-28 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies and method of immunizing therewith |
| WO1990008528A1 (en) | 1989-01-11 | 1990-08-09 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Biologically active synthetic thyrotropin and cloned gene for producing same |
| DK0614975T3 (da) | 1989-05-05 | 2002-11-11 | Genentech Inc | Glycoproteinhormonreceptormolekyler |
| US6261800B1 (en) | 1989-05-05 | 2001-07-17 | Genentech, Inc. | Luteinizing hormone/choriogonadotropin (LH/CG) receptor |
| US5614363A (en) | 1990-01-25 | 1997-03-25 | New England Medical Center Hospitals, Inc. | TSH receptor |
| US5744348A (en) | 1989-09-08 | 1998-04-28 | New England Medical Center Hospitals, Inc. | TSH receptor |
| DE68927461T2 (de) * | 1989-12-14 | 1997-03-20 | B.R.A.H.M.S Diagnostica Gmbh, 12099 Berlin | Polypeptide mit Thyrotropinrezeptor-Aktivität, kodierende Nukleinsäuresequenzen für solche Rezeptoren und Verwendung dieser Polypeptide |
| WO1991009137A1 (en) | 1989-12-20 | 1991-06-27 | Basil Rapoport | Recombinant thyrotropin receptor |
| JPH04149197A (ja) * | 1990-10-12 | 1992-05-22 | Tanabe Seiyaku Co Ltd | 新規ペプチド |
| EP0482598A3 (en) | 1990-10-24 | 1993-05-19 | Ishihara Sangyo Kaisha, Ltd. | Peptide analog of human tsh receptor affective against autoimmune hyperthyroidism |
| US5578496A (en) | 1991-12-19 | 1996-11-26 | Board Of Regents, Baylor College Of Medicine | Detection of autoantibodies associated with the disease myasthenia gravis |
| AU679439B2 (en) | 1992-02-10 | 1997-07-03 | Duke University | Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens |
| US5705400A (en) | 1992-03-07 | 1998-01-06 | Rsr Limited | Assay for adrenal autoantigen |
| US5195860A (en) | 1992-07-20 | 1993-03-23 | Trw Inc. | Push-on type fastener for automatic feed and installation equipment |
| JPH06220089A (ja) * | 1993-01-27 | 1994-08-09 | Ishihara Sangyo Kaisha Ltd | ペプチド又はその塩並びにそれらを含有する自己免疫性甲状腺疾患の診断薬又は治療薬 |
| WO1994018566A1 (fr) | 1993-02-04 | 1994-08-18 | Sumitomo Pharmaceuticals Company, Limited | Procede de dosage d'un anticorps specifique |
| JPH0789991A (ja) * | 1993-09-28 | 1995-04-04 | Mitsubishi Chem Corp | 新規なポリペプチドおよびそれを用いるｔｓｈ受容体抗体の測定法 |
| EP0719858A3 (en) | 1994-12-27 | 1997-12-29 | Tosoh Corporation | Myeloma cell line expressing recombinant human thyroid stimulating hormone receptor |
| DE19505266C1 (de) | 1995-02-16 | 1996-10-02 | Brahms Diagnostica Gmbh | Verwendung von polyklonalen humanen anti-hTg-Autoantikörpern als Reagenz für die klinische Diagnostik von Schilddrüsen-Autoimmunerkrankungen sowie Reagenziensatz für eine Bestimmung von anti-hTg-Autoantikörpern in Patientenseren |
| DE19522171C1 (de) | 1995-06-19 | 1996-08-22 | Brahms Diagnostica Gmbh | Verfahren zur Bestimmung von Anti-TSH-Rezeptor-Autoantikörpern |
| US5723343A (en) | 1995-08-28 | 1998-03-03 | University Of Florida | Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor |
| DE19728991A1 (de) | 1996-11-06 | 1999-02-11 | Brahms Diagnostica Gmbh | Rezeptorbindungsassay, für den Rezeptorbindungsassay geeigneter rekombinanter Fusionsrezeptor, Vektor zu dessen Herstellung sowie Reagenziensatz für die Durchführung des Rezeptorbindungsassays |
| US5734464A (en) | 1996-11-06 | 1998-03-31 | Cobe Laboratories, Inc. | Red blood cell spillover detection technique |
| US6692625B1 (en) | 1996-11-06 | 2004-02-17 | Robert Bosch Gmbh | Electrochemical sensor |
| IL123888A0 (en) | 1997-04-01 | 1998-10-30 | Sankyo Co | Anti-fas antibodies |
| WO2000005345A1 (en) * | 1998-07-21 | 2000-02-03 | Basil Rapoport | Human thyrotropin receptor compositions and use thereof |
| GB9823397D0 (en) * | 1998-10-27 | 1998-12-23 | Rsr Ltd | Assays for thyroid autoantibodies |
| JP4427878B2 (ja) * | 1999-08-20 | 2010-03-10 | 味の素株式会社 | 析出を伴う発酵法によるｌ−グルタミン酸の製造法 |
| ES2248133T3 (es) | 1999-10-12 | 2006-03-16 | Ulrich Loos | Procedimiento para la determinacion de autoanticuerpos contra el receptor de tsh. |
| WO2001044300A2 (en) | 1999-12-13 | 2001-06-21 | Cambridge Antibody Technology Limited | Brain specific binding members |
| DE50106201D1 (de) | 2000-02-21 | 2005-06-16 | Brahms Ag | Verfahren zur differentialdiagnostischen bestimmung von gegen den tsh-rezeptor gebildeten autoantikörpern in einer serum- oder plasmaprobe eines patienten |
| JP5198704B2 (ja) | 2000-03-03 | 2013-05-15 | メディミューン リミティド | エオタキシンに対するヒト抗体及びそれらの使用 |
| US20020103345A1 (en) | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| DE10126968A1 (de) | 2001-06-01 | 2002-12-12 | Ivoclar Vivadent Ag | Farbstoffzusammensetzung zum individuellen Einfärben von Prothesenkunststoffen |
| CN101799476B (zh) | 2001-08-23 | 2013-01-02 | Rsr有限公司 | 筛选针对tsh受体的自身抗体的试剂盒 |
| JP5314234B2 (ja) | 2002-11-29 | 2013-10-16 | アールエスアール リミテッド | チロトロピン受容体の結合対象及びその使用 |
| US8840891B2 (en) * | 2007-02-15 | 2014-09-23 | Rsr Limited | Human monoclonal antibodies to the thyrotropin receptor which act as antagonists |
| EP2617735A3 (en) * | 2008-12-24 | 2013-10-16 | Rsr Limited | Human anti tshr antibodies |
-
2002
- 2002-08-21 CN CN2010101273436A patent/CN101799476B/zh not_active Expired - Lifetime
- 2002-08-21 US US10/488,074 patent/US8298769B2/en not_active Expired - Fee Related
- 2002-08-21 EP EP02755210.8A patent/EP1456234B1/en not_active Expired - Lifetime
- 2002-08-21 WO PCT/GB2002/003831 patent/WO2003018632A2/en not_active Ceased
- 2002-08-21 CN CN201310075812.8A patent/CN103224562B/zh not_active Expired - Lifetime
- 2002-08-21 ES ES11158929T patent/ES2732276T3/es not_active Expired - Lifetime
- 2002-08-21 EP EP11158929.7A patent/EP2383291B1/en not_active Expired - Lifetime
- 2002-08-21 JP JP2003523491A patent/JP2005509412A/ja active Pending
- 2002-08-21 ES ES02755210.8T patent/ES2466377T3/es not_active Expired - Lifetime
- 2002-08-21 EP EP11158927.1A patent/EP2383290B1/en not_active Expired - Lifetime
- 2002-08-21 ES ES11158927T patent/ES2736165T3/es not_active Expired - Lifetime
- 2002-08-21 CN CN028164229A patent/CN1622958B/zh not_active Expired - Lifetime
-
2008
- 2008-12-12 US US12/333,714 patent/US8309693B2/en not_active Expired - Fee Related
- 2008-12-12 US US12/333,740 patent/US8298771B2/en not_active Expired - Fee Related
-
2009
- 2009-07-22 JP JP2009171358A patent/JP5576072B2/ja not_active Expired - Lifetime
-
2012
- 2012-11-09 US US13/673,878 patent/US9751940B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814461A (en) * | 1993-08-20 | 1998-09-29 | B.R.A.H.M.S. Diagnostica Gmbh | Method for the determination of anti-TSH receptor autoantibodies |
| EP0943098B1 (de) * | 1996-12-09 | 2005-03-09 | B.R.A.H.M.S Aktiengesellschaft | Rezeptorbindungsassay zum nachweis von tsh-rezeptor-autoantikörpern |
| EP1021721B1 (en) * | 1998-06-06 | 2006-08-09 | Rsr Limited | Assays for tsh receptor autoantibodies |
| EP1078986B1 (en) * | 1999-08-24 | 2007-02-28 | Tosoh Corporation | Secretory thyroid stimulating hormone receptor (TSHR), and method for assaying anti-TSHR antibody using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| US8298771B2 (en) | 2012-10-30 |
| US8298769B2 (en) | 2012-10-30 |
| EP2383290B1 (en) | 2019-05-08 |
| US9751940B2 (en) | 2017-09-05 |
| WO2003018632A2 (en) | 2003-03-06 |
| EP1456234A2 (en) | 2004-09-15 |
| US20090202438A1 (en) | 2009-08-13 |
| ES2736165T3 (es) | 2019-12-26 |
| JP2005509412A (ja) | 2005-04-14 |
| US20090203036A1 (en) | 2009-08-13 |
| US20130089561A1 (en) | 2013-04-11 |
| WO2003018632A3 (en) | 2004-06-17 |
| EP2383291A2 (en) | 2011-11-02 |
| EP2383290A2 (en) | 2011-11-02 |
| ES2732276T3 (es) | 2019-11-21 |
| EP1456234B1 (en) | 2014-04-09 |
| CN103224562A (zh) | 2013-07-31 |
| CN103224562B (zh) | 2017-09-08 |
| ES2466377T3 (es) | 2014-06-10 |
| JP5576072B2 (ja) | 2014-08-20 |
| CN1622958B (zh) | 2013-04-03 |
| EP2383290A3 (en) | 2012-10-10 |
| EP2383291B1 (en) | 2019-04-17 |
| CN1622958A (zh) | 2005-06-01 |
| CN101799476A (zh) | 2010-08-11 |
| US8309693B2 (en) | 2012-11-13 |
| EP2383291A3 (en) | 2013-02-13 |
| US20050118638A1 (en) | 2005-06-02 |
| JP2009278998A (ja) | 2009-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101799476B (zh) | 筛选针对tsh受体的自身抗体的试剂盒 | |
| EP0783104A1 (en) | Method for assaying soluble amyloid precursor protein | |
| JP2009278998A5 (OSRAM) | ||
| US20030148333A1 (en) | HCV anti-core monoclonal antibodies | |
| EA023406B1 (ru) | Антитела к гепцидину и варианты их применения | |
| WO1993002358A1 (en) | Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies oxa and oxb | |
| US10494430B2 (en) | Anti-active GIP antibody | |
| KR102450481B1 (ko) | 돼지열병 바이러스 특이적인 항체 및 이의 용도 | |
| CA2531995A1 (en) | Methods, kits and antibodies for detecting parathyroid hormone | |
| JP2729159B2 (ja) | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 | |
| WO2006002774A1 (en) | Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding their variable regions, and their uses in diagnostic, preventive and therapeutic medicine | |
| JP3894381B2 (ja) | 抗Ｇｌｕ▲１７▼−オステオカルシン抗体 | |
| KR100493932B1 (ko) | 레지스틴에 대한 단클론 항체, 이의 제조 방법, 및 용도 | |
| JPH10179186A (ja) | 抗ヒトカルシトニンモノクローナル抗体 | |
| CN117106074A (zh) | 抗狂犬病毒糖蛋白抗体或其片段及其应用 | |
| JP2011160696A (ja) | 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体 | |
| JP2007045834A (ja) | 抗Ｇｌｕ１７−オステオカルシン抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20130102 |
|
| CX01 | Expiry of patent term |